119 related articles for article (PubMed ID: 34813779)
41. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
Srivastava A; Moorthy A
Front Biosci (Schol Ed); 2019 Mar; 11(1):193-202. PubMed ID: 30844744
[TBL] [Abstract][Full Text] [Related]
45. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
46. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
47. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
48. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
49. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
50. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.
Chen TJ; Zhou YF; Ning JJ; Yang T; Ren H; Li Y; Zhang S; Chen MW
Cell Physiol Biochem; 2015; 36(3):893-906. PubMed ID: 26065336
[TBL] [Abstract][Full Text] [Related]
51. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
52. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
53. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
Wu PK; Hong SK; Park JI
Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
[TBL] [Abstract][Full Text] [Related]
54. Cholesterol neutralized vemurafenib treatment by promoting melanoma stem-like cells via its metabolite 27-hydroxycholesterol.
Wang X; Zhong F; Chen T; Wang H; Wang W; Jin H; Li C; Guo X; Liu Y; Zhang Y; Li B
Cell Mol Life Sci; 2024 May; 81(1):226. PubMed ID: 38775844
[TBL] [Abstract][Full Text] [Related]
55. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
56. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
57. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
58. Rescue of cell cycle progression in BRAF
Toress-Collado AX; Nazarian R; Jazirehi AR
Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
[TBL] [Abstract][Full Text] [Related]
59. The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.
Jiang SL; Wang ZB; Zhu T; Jiang T; Fei JF; Liu C; Luo C; Cheng Y; Liu ZQ
Front Pharmacol; 2021; 12():720619. PubMed ID: 34512348
[TBL] [Abstract][Full Text] [Related]
60. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
